Nancy M. Hardy - Concepedia

Author

Nancy M. Hardy

Also Known As

Dr. Nancy Maureen Hardy, N Hardy, N M Hardy, N. Hardy, N. M. Hardy, N.M. Hardy, Nancy Hardy, Nancy M Hardy, Nancy M. Hardy, Nancy Maureen Hardy

156

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

University of Maryland, Baltimore National Cancer Institute National Institutes of Health Center for Cancer Research University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

About

Nancy M. Hardy is an author at University of Maryland, Baltimore specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	1.1K
2	Cellular Therapies	5	5	174
3	Health Sciences	4	4	123
4	Blood Transplantation	2	2	65
5	Cell Biology	1	1	832

Nancy M. Hardy

Publications

2.8K

Citations

H-Index

Page 1

	Year	Citations
NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma Aaron P. Rapoport, Edward A. Stadtmauer, Gwendolyn Binder-Scholl, Nature Medicine Cancer ImmunosurveillanceImmunologyTumor ImmunityImmune Checkpoint InhibitorAntigen-specific Antitumor Effects	2015	832
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation James N. Kochenderfer, Mark E. Dudley, Robert O. Carpenter, Blood	2013	586
National Marrow Donor Program–Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide Bronwen E. Shaw, Antonio Martin Jimenez-Jimenez, Linda J. Burns, Journal of Clinical Oncology	2021	198
Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation Marcos de Lima, David L. Porter, Minoo Battiwalla, Biology of Blood and Marrow Transplantation	2013	139
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation David Porter, Edwin P. Alyea, Joseph H. Antin, Biology of Blood and Marrow Transplantation	2010	138
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation Michael Bishop, Robert M. Dean, Seth M. Steinberg, Annals of Oncology Lymphoid NeoplasiaCell TherapyTransplantationMarrow TransplantationStem Cell Transplantation	2008	78
Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers Jeffrey I. Cohen, Lesia Dropulic, Amy P. Hsu, Clinical Infectious Diseases	2016	70
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial Zachary Crees, Michael P. Rettig, Reyka G. Jayasinghe, Nature Medicine	2023	68
Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation Jean A. Yared, Nancy M. Hardy, Zeba N. Singh, Bone Marrow Transplantation Lymphoid NeoplasiaCell TherapyTransplantationMarrow TransplantationRelapsed/refractory Hodgkin Lymphoma	2016	55
A Phase II Study of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Ashraf Badros, Mehmet H. Kocoglu, Ning Ma, Blood	2015	55

Page 1